Inhibition of mTORC1 by rapamycin results in the hyperactivation of p-AKT pathway, by the stimulation of mTORC2 and, consequently in enhanced survival and chemoresistance of MM-PCs [13, 20, 37]. Here, AKT1 is linked to Miyoshi myopathy.